H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Disc Medicine today and set a price target of $118.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Douglas Tsao has given his Buy rating due to a combination of factors including the promising potential of Disc Medicine’s lead candidate, bitopertin, for treating Erythropoietic Protoporphyria (EPP). The mechanism of action of bitopertin suggests it could prevent liver damage, a significant concern for EPP patients, by reducing the accumulation of PPIX, which is linked to liver complications. Recent data from the HELIOS study showed improvements in liver-related biomarkers and quality of life for patients, reinforcing confidence in bitopertin’s efficacy.
Additionally, the safety profile of bitopertin is noteworthy, with long-term studies indicating only mild adverse effects, making it suitable for lifelong treatment. The company’s strategic preparations for a 2026 launch, including expanding their commercial team and engaging with healthcare providers, further support the potential for successful market entry. These elements combined underscore the strong investment case for Disc Medicine, justifying the Buy rating.
In another report released on June 17, BMO Capital also reiterated a Buy rating on the stock with a $120.00 price target.